QUAGLINO, Pietro
QUAGLINO, Pietro
SCIENZE MEDICHE
1975-2011 Overall Survival, Disease Free Survival and Survival after Recurrence across gender in melanoma patients: what has changed?
2012-01-01 Simone Ribero; Pietro Quaglino; Martina Sanlorenzo; Simona Osella-Abate; Federica Marenco; Tiziana Nardò; Giuseppe Macripò; Maria Teresa Fierro; Maria Grazia Bernengo
262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study
2017-01-01 Kim, Y.H.; Whittaker, S.; Horwitz, S.M.; Duvic, M.; Dummer, R.; Scarisbrick, J.; Quaglino, P.; Zinzani, P.; Wolter, P.; Wang, Y.; Palanca-Wessels, M.; Zagadailov, E.; Trepicchio, W.L.; Lin, H.; Little, M.; Prince, H.
A multicenter, d ouble blind, randomized, placebo-controlled, phase II trial to evaluate resminostat for maintenance treatment of patients with advanced stage (stage IIB–IVB) mycosis fungoides (MF) or Sézary syndrome (SS) that have achieved disease control with systemic therapy: the RESMAIN study
2019-01-01 Stadler, R.; Scarisbrick, J.; Knobler, R.; Quaglino, P.; Borgmann, M.; Orlovius, M.; Reimann, P.; Danhauser-Riedl, S.
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients.
2011-01-01 Simona Rolla; Valentina Bardina; Marinella Clerico; Paola Bonaventura; Pietro Quaglino; Giulia Contessa; Luca Durelli; Francesco Novelli
Abstract 5603: Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies
2017-01-01 Sanlorenzo, Martina; Vujic, Igor; Floris, Arianna; Novelli, Mauro; Donini, Chiara; Gammaitoni, Loretta; Giraudo, Lidia; Macagno, Marco; Quaglino, Pietro; Fierro, Maria Teresa; Giordano, Silvia; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sangiolo, Dario
Activity and safety of bexarotene as maienance therapy in CTCL patients with stable disease or remission after systemic treatments: a prospective multicenter trial from the GILC
2011-01-01 Quaglino P
Activity and safety of bexarotene as maintainance therapy in advanced/aggressive CTCL patients with stable disease or remission after systemic treatment: an observational multicenter trial from the GILC
2007-01-01 Pietro Quaglino; Maria Grazia Bernengo
Activity and safety of Bexarotene as maintenance therapy in CTCL patients (Mycosis Fungoides stage IIB-IV, Sezary Syndrome, peripheral T-cell lymphoma) with stable disease or remission after systemic treatments: A prospective multicenter trauil from the Italian Group of Cutaneous Lymphoma (GILC)
2011-01-01 Quaglino P;Pimpinelli N; Alaibac M; Quintini G; Bernengo MG
Alemtuzumab - low dose therapy schedule effective for CTCL
2011-01-01 Quaglino Pietro
Alemtuzumab for the treatment of Sézary sindrome: clinical and immunological findings in 10 patients.
2006-01-01 Bernengo MG; Quaglino P; Comessatti A; Ortoncelli M; Novelli M; Fierro MT.
Alemtuzumab nel trattamento dei linfomi cutanei a cellule T in fase avanzata: studio pilota “dose finding”.
2004-01-01 Savoia P; Fierro MT; Quaglino P; Peroni A; Comessatti A; Bernengo MG.
Alterazioni funzionali e fenotipiche dei polimorfonucleati nei pazienti affetti da dermatite atopica
2011-01-01 Banche G; Allizond V; Novelli M; Fierro MT; Mandras N; Murabito P; Quaglino P; Scalas D; Merlino C; Roana J; Tullio V; Bernengo MG; Cuffini AM
Alterazioni funzionali e fenotipiche dei polimorfonucleati nella sindrome di sezary
2009-01-01 G. Banche; M.T. Fierro; M. Novelli; V. Allizond; A. Comessatti; P. Quaglino; D. Scalas; C. Merlino; M.G. Bernengo; A Cuffini
An international multi-institutional study for the evaluation of folliculotropic mycosis fungoides: results of the Consensus Histopathologic Review
2019-01-01 Gru, Alejandro A.; Mitteldorf, Christina; Pulitzer, Melissa; Hodak, Emmilia; Scarisbrick, Julia; Zic, John; Kempf, Werner; Guenova, Emmanuela; Haun, Paul; Torres-Cabala, Carlos; Robson, Alistair; Querfeld, Christiane; Junkins-Hopkins, Jacqueline; Cozzio, Antonio; Papadavid, Lia; Quaglino, Pietro; Beltraminelli, Helmut; Knobler, Robert; Stadler, Rudi; Geskin, Larisa; Bagot, Martine; Subtil, Antonio; Sanches, Jose A.; Guitart, Joan; Rooke, Bethanie; Duvic, Madeleine; Ortiz, Pablo; Kim, Youn; Battistella, Maxime
Associazione di ciclofosfamide, vincristina e prednisone (COP) nel trattamento dei linfomi cutanei: 20 anni di follow-up.
1996-01-01 Fierro MT; Verrone A; Savoia P; Quaglino P; Doveil GC; Bernengo MG
Associazione di etoposide, idarubicina, ciclofosfamide, vincristina, prednisone e bleomicina (VICOP-B) nel trattamento dei linfomi cutanei
1995-01-01 Doveil GC; Fierro MT; Appino A; Quaglino P; Savoia P
Autoantibody profile in 619 italian patients with cutaneous lupus erythematosus
2018-01-01 Verdelli, A; Coi, A; Marzano, A; Antiga, E; Cozzani, E; Quaglino, P; La Placa, M; Benucci, M; De Simone, C; Papini, M; Parodi, A; Bianchi, F; Caproni, M
Biological prognostic factors in advanced metastatic melanoma patients treated with chemoimmunotheraphy.
1997-01-01 Fierro MT; Quaglino P; Lisa F; Savoia P; Bernengo MG
Bullous pemphigoid is characterised by a reduction of skin-homing/circulating FOXP3+ Tregs and by a down-regulation of the IL-10 pathway
2012-01-01 Quaglino P; Antiga E; Novelli M; Nardò T; Fava P; Ponti R; Osella-Abate S; Caproni M; Fabbri P; Bernengo MG
CD26 (DPP-IV)- A useful marker in Sezary sindrome
1994-01-01 Novelli M; Fierro MT; Quaglino P; Lisa F; Doveil GC; Bernengo MG